A Phase 4, Open-Label, Randomized Study of Two Inotuzumab Ozogamicin Dose Levels in Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic leukemia Eligible for Hematopoietic Stem Cell Transplantation and Who Have Risk Factor(s) for Veno-Occlusive Disease.

  • Fleming, Shaun Alan, (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

StatusActive
Effective start/end date9/07/19 → 31/12/25
View all
View less

Keywords

  • Malignant Haematology
  • Acute lymphoblastic leukaemia (ALL)
  • Clinical trial